Form 8-K Inmune Bio, Inc. For: Jun 27
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- KKR launches Helix with over $10 billion to build AI infrastructure
BTIG Downgrades INmune Bio Inc. (INMB) to Neutral
June 30, 2025 4:37 PM EDTBTIG analyst Thomas Shrader downgraded INmune Bio Inc. (NASDAQ: INMB) from Buy to Neutral.
The analyst comments "A solid MAYBE but with no clear way forward and management talking about moving to other programs - so NEUTRAL makes sense. The size of the AD opportunity hasn't changed, so the current stock price (about $2 all day) equates to a probability of success in AD of 0% with all revenues coming from MDD. Our two biggest worries going into this readout (preview HERE) were: 1) the modest enrichment in the MINDFul trial population, based on one (of four)... More
